Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6606181 | 1.00 | AKR1B1 (0.33) | AKR1B1MAP3K14 | |
| SCHEMBL6583197 | 0.80 | AKR1B1 (0.45) | AKR1B1MAP3K14 | |
| SCHEMBL6605186 | 0.79 | AKR1B1 (0.42) | AKR1B1MAP3K14 | |
| SCHEMBL6580397 | 0.79 | AKR1B1 (0.42) | AKR1B1MAP3K14 | |
| SCHEMBL6605188 | 0.79 | AKR1B1 (0.42) | AKR1B1MAP3K14 | |
| SCHEMBL6580562 | 0.73 | PTGS1 (0.39) | AKR1B1 | |
| SCHEMBL5399558 | 0.73 | MEN1 (0.36) | AKR1B1 | |
| SCHEMBL5399566 | 0.73 | MEN1 (0.36) | AKR1B1 | |
| SCHEMBL5399150 | 0.73 | PPARD (0.32) | AKR1B1MAP3K14 | |
| SCHEMBL6582062 | 0.70 | AKR1B1 (0.41) | AKR1B1MAP3K14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716834-B2 | ANTICOAGULANTS. | ASTRAZENECA AB (SE) | 2004-04-06 | — | — | US | disclosed |
| EP-1283837-B1 | NEW THIOCHROMANE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-02-25 | — | — | EP | disclosed |
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220317-A1 | Thiochromane derivatives and their use as thrombin inhibitors | SERPINC1, F2, TFPI | AKR1B1 1031/4885MAP3K14 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.